In vitro activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant Staphylococcus aureus.

Conclusion: Lysostaphin causes rapid lysis of S. aureus. Combination therapies that include linezolid and lysostaphin could be used in life-threatening infections, such as endocarditis to increase the early in vivo activity of the antibiotics, and to prevent the emergence of linezolid resistant mutants. Further, in vivo studies are warranted to confirm our results. PMID: 29238455 [PubMed]
Source: Iranian Journal of Microbiology - Category: Microbiology Tags: Iran J Microbiol Source Type: research